Fulcrum Therapeutics, Inc.
FULC
$3.74
$0.030.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -26.18M | -18.89M | -20.33M | -19.60M | -17.30M |
| Total Depreciation and Amortization | 216.00K | 338.00K | 347.00K | 346.00K | 344.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.55M | 3.09M | 2.68M | 2.77M | 1.79M |
| Change in Net Operating Assets | 2.38M | -3.29M | 506.00K | 2.29M | 1.34M |
| Cash from Operations | -16.04M | -18.75M | -16.80M | -14.19M | -13.82M |
| Capital Expenditure | -108.00K | -8.00K | -159.00K | -90.00K | -65.00K |
| Sale of Property, Plant, and Equipment | 450.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 13.44M | -128.20M | -890.00K | 18.70M | 14.00M |
| Cash from Investing | 13.78M | -128.21M | -1.05M | 18.61M | 13.93M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 356.00K | 21.00K | 168.30M | 64.00K | 301.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -333.00K | -- | -- | -- |
| Cash from Financing | 356.00K | -312.00K | 168.30M | 64.00K | 301.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.90M | -147.27M | 150.46M | 4.49M | 414.00K |